Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Veru Inc | VERU | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.42 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.36 - 1.92 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.42 | USD |
Veru Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
207.86M | 146.38M | - | 16.3M | -93.09M | -0.64 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Veru News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERU Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.42 | 1.57 | 1.25 | 1.42 | 1,632,137 | 0.00 | 0.00% |
1 Month | 1.29 | 1.75 | 1.17 | 1.43 | 2,194,297 | 0.13 | 10.08% |
3 Months | 0.5531 | 1.92 | 0.54 | 1.23 | 2,464,101 | 0.8669 | 156.73% |
6 Months | 0.98 | 1.92 | 0.36 | 0.9357665 | 2,163,896 | 0.44 | 44.90% |
1 Year | 1.14 | 1.92 | 0.36 | 0.9739159 | 1,623,772 | 0.28 | 24.56% |
3 Years | 8.3408 | 24.55 | 0.36 | 10.32 | 4,391,222 | -6.92 | -82.98% |
5 Years | 1.65 | 24.56 | 0.36 | 10.15 | 3,269,314 | -0.23 | -13.94% |
Veru Description
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States. |